Press Release Archives

Tevogen CIO and Head of Tevogen.AI Mittul Mehta to Speak at Microsoft Fabric Community Conference (FabCon 2026)     March 18, 2026   WARREN, N.J., Tevogen Bio Holdings Inc. (“Tevogen” or the “Company) (Nasdaq: TVGN) today announced that Mittul Mehta, Chief Information Officer and Head of Tevogen.AI, will speak at the Microsoft Fabric Community ConferenceContinue reading “Tevogen CIO and Head of Tevogen.AI Mittul Mehta to Speak at Microsoft Fabric Community Conference (FabCon 2026)”

Tevogen Reaffirms Capital Discipline as Lead Investor Maintains Holdings and Company Limits Share Utilization   Lead investor confirmed his intention to maintain his current shareholdings. Company does not anticipate using more than 1% of our authorized shares, including placement through the ATM, over the next 12 months or until the company becomes cash-flow positive. ApproximatelyContinue reading “Tevogen Reaffirms Capital Discipline as Lead Investor Maintains Holdings and Company Limits Share Utilization”

Tevogen.AI Reports Advancements in PredicTcell™ Beta, Demonstrates Improved Precision Metrics and Expands Proprietary AI Infrastructure     March 13, 2026   WARREN, N.J., Tevogen Bio Holdings Inc. (“Tevogen” or the “Company) (Nasdaq: TVGN) today announced performance advancements for its artificial intelligence platform, operated through Tevogen.AI.   Tevogen.AI was built to solve a critical challenge inContinue reading “Tevogen.AI Reports Advancements in PredicTcell™ Beta, Demonstrates Improved Precision Metrics and Expands Proprietary AI Infrastructure”

Tevogen CEO Dr. Ryan Saadi Reaffirms Clinical Commitment During International Long COVID Awareness Month; Highlights Synergies of New Leadership Team and Digital Care Platform     March 11, 2026   WARREN, N.J., Tevogen Bio Holdings Inc. (“Tevogen” or the “Company) (Nasdaq: TVGN) today issued a statement from Founder and CEO Dr. Ryan Saadi regarding theContinue reading “Tevogen CEO Dr. Ryan Saadi Reaffirms Clinical Commitment During International Long COVID Awareness Month; Highlights Synergies of New Leadership Team and Digital Care Platform”

Tevogen Names Leadership Team to Execute Diversified Growth Strategy     March 9, 2026   WARREN, N.J., Tevogen Bio Holdings Inc. (“Tevogen” or the “Company) (Nasdaq: TVGN) today announced the appointment of interim leaders across its core business verticals to execute the first phase of its diversified growth strategy.   In this first phase, TevogenContinue reading “Tevogen Names Leadership Team to Execute Diversified Growth Strategy”

Letter to Shareholders from CEO Dr. Ryan Saadi       March 6, 2026   WARREN, N.J., Tevogen Bio Holdings Inc. (“Tevogen” or the “Company) (Nasdaq: TVGN).   Dear Shareholders,   As we continue executing on Tevogen’s long-term strategy to evolve into a sustainable, revenue-generating healthcare enterprise, I would like to provide an update regardingContinue reading “Letter to Shareholders from CEO Dr. Ryan Saadi”

Tevogen Advances Generics Strategy, Signs Letter of Intent to Evaluate Potential Acquisition of Apozeal Pharmaceutical       March 5, 2026   WARREN, N.J., Tevogen Bio Holdings Inc. (“Tevogen” or the “Company) (Nasdaq: TVGN), today announced that it has entered into a signed, non-exclusive, non-binding Letter of Intent (“LoI”) to evaluate a potential transaction with SciometrixContinue reading “Tevogen Advances Generics Strategy, Signs Letter of Intent to Evaluate Potential Acquisition of Apozeal Pharmaceutical”

Tevogen Announces Reverse Stock Split       March 4, 2026   WARREN, N.J., Tevogen Bio Holdings Inc. (“Tevogen” or the “Company) (Nasdaq: TVGN), today announced that its Board of Directors (the “Board”) has approved a reverse stock split of its common stock at a ratio of 50 for 1. Stockholders previously approved the reverseContinue reading “Tevogen Announces Reverse Stock Split”

Tevogen Signs Letter of Intent to Evaluate Potential Acquisition of a Contract Research Organization       February 27, 2026   WARREN, N.J., Tevogen Bio Holdings Inc. (“Tevogen” or the “Company) (Nasdaq: TVGN), today announced that it has entered into a signed, non-exclusive, non-binding Letter of Intent (“LoI”) to evaluate a potential transaction with aContinue reading “Tevogen Signs Letter of Intent to Evaluate Potential Acquisition of a Contract Research Organization”

UPDATE – Tevogen Signs Letter of Intent to Evaluate Potential Acquisition of Sciometrix and its Digital Care Management Platform Clinicus       February 26, 2026   WARREN, N.J., Tevogen Bio Holdings Inc. (“Tevogen” or the “Company) (Nasdaq: TVGN), today announced that it has entered into a signed, non-exclusive, non-binding Letter of Intent (“LoI”) toContinue reading “UPDATE – Tevogen Signs Letter of Intent to Evaluate Potential Acquisition of Sciometrix and its Digital Care Management Platform Clinicus”